Stay updated with breaking news from Fb 088. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
InFlectis BioScience Doses First Patient with IFB-088 in a Phase 2 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
InFlectis BioScience granted Orphan Drug Designation for IFB-088 (icerguastat), a clinical stage treatment for Amyotrophic Lateral Sclerosis
InFlectis BioScience Receives Approval from French Regulatory Authority to Conduct a Phase 2 Clinical Trial for IFB-088 (Icerguastat) for the Treatment of